Evidence map›Paper›PMID 26091203›Full record

ArticleThe Journal of clinical endocrinology and metabolism2015

Epidemiology of Dysglycemia in Pregnant Oklahoma American Indian Women.

Madona Azar, Julie A Stoner, Hanh Dung Dao, Lancer Stephens, Jean R Goodman, John Maynard, Timothy J Lyons

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Madona AzarSection of Endocrinology, Diabetes, and Metabolism (M.A.), Oklahoma Shared Clinical and Translational Resources (L.S.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73014; Department of Biostatistics and Epidemiology (J.A.S., H.D.D.), College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104; Division of Maternal and Fetal Medicine (J.R.G.), Loyola University Medical Center, Maywood, Illinois 60153; Medical Device and Diagnostics Consulting (J.M.), Albuquerque, New Mexico; and Centre for Experimental Medicine (T.J.L.), Queen's University of Belfast, Belfast BT7 1NN, Northern Ireland, United Kingdom.
Julie A StonerSection of Endocrinology, Diabetes, and Metabolism (M.A.), Oklahoma Shared Clinical and Translational Resources (L.S.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73014; Department of Biostatistics and Epidemiology (J.A.S., H.D.D.), College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104; Division of Maternal and Fetal Medicine (J.R.G.), Loyola University Medical Center, Maywood, Illinois 60153; Medical Device and Diagnostics Consulting (J.M.), Albuquerque, New Mexico; and Centre for Experimental Medicine (T.J.L.), Queen's University of Belfast, Belfast BT7 1NN, Northern Ireland, United Kingdom.
Hanh Dung DaoSection of Endocrinology, Diabetes, and Metabolism (M.A.), Oklahoma Shared Clinical and Translational Resources (L.S.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73014; Department of Biostatistics and Epidemiology (J.A.S., H.D.D.), College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104; Division of Maternal and Fetal Medicine (J.R.G.), Loyola University Medical Center, Maywood, Illinois 60153; Medical Device and Diagnostics Consulting (J.M.), Albuquerque, New Mexico; and Centre for Experimental Medicine (T.J.L.), Queen's University of Belfast, Belfast BT7 1NN, Northern Ireland, United Kingdom.
Lancer StephensSection of Endocrinology, Diabetes, and Metabolism (M.A.), Oklahoma Shared Clinical and Translational Resources (L.S.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73014; Department of Biostatistics and Epidemiology (J.A.S., H.D.D.), College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104; Division of Maternal and Fetal Medicine (J.R.G.), Loyola University Medical Center, Maywood, Illinois 60153; Medical Device and Diagnostics Consulting (J.M.), Albuquerque, New Mexico; and Centre for Experimental Medicine (T.J.L.), Queen's University of Belfast, Belfast BT7 1NN, Northern Ireland, United Kingdom.
Jean R GoodmanSection of Endocrinology, Diabetes, and Metabolism (M.A.), Oklahoma Shared Clinical and Translational Resources (L.S.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73014; Department of Biostatistics and Epidemiology (J.A.S., H.D.D.), College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104; Division of Maternal and Fetal Medicine (J.R.G.), Loyola University Medical Center, Maywood, Illinois 60153; Medical Device and Diagnostics Consulting (J.M.), Albuquerque, New Mexico; and Centre for Experimental Medicine (T.J.L.), Queen's University of Belfast, Belfast BT7 1NN, Northern Ireland, United Kingdom.
John MaynardSection of Endocrinology, Diabetes, and Metabolism (M.A.), Oklahoma Shared Clinical and Translational Resources (L.S.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73014; Department of Biostatistics and Epidemiology (J.A.S., H.D.D.), College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104; Division of Maternal and Fetal Medicine (J.R.G.), Loyola University Medical Center, Maywood, Illinois 60153; Medical Device and Diagnostics Consulting (J.M.), Albuquerque, New Mexico; and Centre for Experimental Medicine (T.J.L.), Queen's University of Belfast, Belfast BT7 1NN, Northern Ireland, United Kingdom.
Timothy J LyonsSection of Endocrinology, Diabetes, and Metabolism (M.A.), Oklahoma Shared Clinical and Translational Resources (L.S.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73014; Department of Biostatistics and Epidemiology (J.A.S., H.D.D.), College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104; Division of Maternal and Fetal Medicine (J.R.G.), Loyola University Medical Center, Maywood, Illinois 60153; Medical Device and Diagnostics Consulting (J.M.), Albuquerque, New Mexico; and Centre for Experimental Medicine (T.J.L.), Queen's University of Belfast, Belfast BT7 1NN, Northern Ireland, United Kingdom.
University of Oklahoma Health Sciences Center · USLoyola University Medical Center · US

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI JENNIFER DAVID PECK · 2013 to 2026
$68.2M
NIGMS NIH HHS 1 U54GM104938NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

contextMinority communities are disproportionately affected by diabetes, and minority women are at an increased risk for glucose intolerance (dysglycemia) during pregnancy.

objectivesIn pregnant American Indian women, the objectives of the study were to use current criteria to estimate the prevalence of first-trimester (Tr1) dysglycemia and second-trimester (Tr2) incidence of gestational diabetes mellitus (GDM) and to explore new candidate measures and identify associated clinical factors.

designThis was a prospective cohort study. In Tr1 we performed a 75-g, 2-hour oral glucose tolerance test (OGTT) and glycated hemoglobin (HbA1c) to determine the following: fasting insulin; homeostasis model assessment of insulin resistance; serum 1,5-anhydroglucitol; noninvasive skin autofluorescence (SCOUT). We defined dysglycemia by American Diabetes Association and Endocrine Society criteria and as HbA1c of 5.7% or greater. In Tr2 in an available subset, we performed a repeat OGTT and SCOUT.

participantsPregnant American Indian women (n = 244 at Tr1; n = 114 at Tr2) participated in the study. OUTCOMES: The prevalence of dysglycemia at Tr1 and incidence of GDM at Tr2 were measured.

resultsAt Tr1, one woman had overt diabetes; 36 (15%) had impaired glucose tolerance (American Diabetes Association criteria and/or abnormal HbA1c) and 59 (24%) had GDM-Tr1 (Endocrine Society criteria). Overall, 74 (30%) had some form of dysglycemia. Associated factors were body mass index, hypertension, waist/hip circumferences, SCOUT score, fasting insulin, and homeostasis model assessment of insulin resistance. At Tr2, 114 of the Tr1 cohort underwent a repeat OGTT and SCOUT, and 26 (23%) had GDM. GDM-Tr2 was associated with increased SCOUT scores (P = .029) and Tr1 body mass index, waist/hip circumferences, diastolic blood pressure, fasting insulin, and triglyceride levels. Overall, dysglycemia at Tr1 and/or Tr2 affected 38% of the women.

conclusionsDysglycemia at some point during pregnancy was common among American Indian women. It was associated with features of insulin resistance and may confer long-term health risks for mother and child.

Indexed as

AdolescentAdultCohort StudiesDiabetes, GestationalFemaleGlucose IntoleranceGlucose Tolerance TestHumansIndians, North AmericanOklahomaPregnancyPregnancy ComplicationsPregnancy Trimester, FirstPregnancy Trimester, SecondPrevalenceYoung Adult

Identifiers

PMID26091203
PMCPMC4525008
OpenAlexW1920459297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.